Filibuvir

Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp) . Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively[1]. Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation[2].

Product Specifications

CAS Number

[877130-28-4]

UNSPSC

12352005

Target

DNA/RNA Synthesis; HCV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

Neuroscience-Neuromodulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/filibuvir.html

Purity

99.0

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

O=C(O1)C(CC2=NN(C(C)=C3)C(N=C3C)=N2)=C(O)C[C@@]1(C4CCCC4)CCC5=CC(CC)=NC(CC)=C5

Molecular Formula

C29H37N5O3

Molecular Weight

503.64

References & Citations

[1]Wagner F, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011 Jul;54 (1) :50-9.|[2]Guanghui Yi, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012 Feb;56 (2) :830-7.